GlassScriptPhysician profile
Richmond D Mccarty
NPI 1487632188
$6,047.74
in general payments reported to CMS, 2019-2025
40 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $284 · 2021: $646 · 2022: $979 · 2023: $1,330 · 2024: $825 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $727.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $712.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.25 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $430.74 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $400.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $341.68 | 2020-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $236.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.35 | 2020-2023 | Xifaxan |
| Bausch Health US, LLC | $147.50 | 2020-2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $130.43 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $128.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $124.91 | 2023-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $93.66 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $73.28 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richmond Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.